Emerging Paradigms in Immune-Focused Drug Discovery
Abstract
Recent patent disclosures highlight a conceptual shift in drug discovery, integrating targeted protein degradation with functional precision oncology. IRAK-M and IRAK4 degraders exemplify how innate immune signaling can be rewired through selective protein removal, while patient-derived microcancer platforms provide a decision framework for rationally deploying such agents. Together, these inventions redefine how molecular precision and biological context converge to guide translational success.
Fields of Study & Subjects
Protein Degradation and Inhibitors
Cancer Immunotherapy and Biomarkers
Immunotherapy and Immune Responses
Publication details
- Journal / source
- ACS Medicinal Chemistry Letters
- Volume
- 17
- Issue
- 3
- Pages
- 631–633
- Publication date
- 23 February 2026
- Language
- EN